Max Hasmann

3.0k citations
49 papers · 2.3k · 2 hit papers · h-index 23

Impact in

    • Sirtuins and Resveratrol in Medicine
  • Oncology top 2%
    • HER2/EGFR in Cancer Research
    • PARP inhibition in cancer therapy
    • Peptidase Inhibition and Analysis

Papers in

Max Hasmann

45 papers receiving 2.2k citations

Max Hasmann's Hit Papers

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models 2009 · 466 citations
4660+7+15Years since publication100200300400500

Peers

Max Hasmann
Comparison fields: 5 of 108
  • Geriatrics and Gerontology 360
  • Oncology 1.3k
  • Physiology 217
  • Radiology, Nuclear Medicine and Imaging 615
  • Biological Psychiatry 29
Replace Anna Garuti with:
Anna Garuti Italy
Katherine M. Aird United States
Raymond E. Moellering United States
Ali R. Jazirehi United States
Kwang Woon Kim United States
Kirsteen H. Maclean United States
Carolyn Cao United States
Jianping Xiong China
Zhihong Xu China
Shunrong Ji China
Max Hasmann relative to Anna Garuti Italy Anna Garuti's profile →
Citations per field
00.5×11.6×
Anna Garuti · 1×
Citations per year

Countries citing papers authored by Max Hasmann

Since Specialization
Citations

This map shows the geographic impact of Max Hasmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hasmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hasmann more than expected).

Fields of papers citing papers by Max Hasmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Hasmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hasmann. The network helps show where Max Hasmann may publish in the future.

Co-authors

The 25 scholars most cited alongside Max Hasmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Max Hasmann Line = papers co-authored together Max Hasmann links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Hit paper breakdown →
2003513
2
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Hit paper breakdown →
2009466
3 201391
4 200579
5
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.
200279
6 200578
7 201263
8 201859
9 198956
10 201353
11
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
200651
12 200750
13 199448
14 201145
15 201844
16 199542
17 200941
18 199340
19 201739
20 201238

About Max Hasmann

Max Hasmann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Immunology and Allergy and Genetics, having authored 49 papers that have together received 2.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (25 papers), Monoclonal and Polyclonal Antibodies Research (19 papers), Cell Adhesion Molecules Research (7 papers), Estrogen and related hormone effects (5 papers), Glycosylation and Glycoproteins Research (4 papers), Cancer therapeutics and mechanisms (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cell death mechanisms and regulation (3 papers). The work is most often cited by research in Geriatrics and Gerontology (360 citations), Oncology (1.3k citations), Physiology (217 citations), Radiology, Nuclear Medicine and Imaging (615 citations) and Biological Psychiatry (29 citations). Max Hasmann has collaborated with scholars based in Germany, United Kingdom and Switzerland. Frequent co-authors include Thomas Friess, Werner Scheuer, Birgit Bossenmaier, Josef Endl, Helmut Burtscher, R. Löser, Benno Rattel, Simon P. Langdon, Katja Wosikowski and Peter Mullen. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Biochemical Pharmacology, Cancer Treatment Reviews and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact